Video Experimental Relacionado
Updated: Aug 18, 2026
07:09
Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
Published on: April 1, 2015
Los niveles elevados de beta-tromboglobulina y los agregados de plaquetas circulantes en la microangiopatía diabética
Lancet (London, England)
|February 4, 1978
Resumen
La microangiopatía diabética está relacionada con el aumento de la beta-tromboglobulina (una proteína plaquetaria) y la activación plaquetaria. La mejora del control de la glucosa en sangre en diabéticos redujo significativamente los niveles de beta-tromboglobulina.
Área de la Ciencia:
- La bioquímica es la bioquímica.
- Hematología Hematología.
- Endocrinología Endocrinología.
Sus antecedentes:
- La microangiopatía diabética es una complicación común de la diabetes mellitus.
- La activación plaquetaria juega un papel potencial en la patogénesis de las enfermedades microvasculares.
Objetivo del estudio:
- Para investigar la relación entre los niveles de beta-tromboglobulina, la agregación plaquetaria y la microangiopatía diabética.
- Para evaluar el impacto del control glucémico en estos marcadores.
Principales métodos:
- Se recogieron muestras de sangre de controles sanos y pacientes diabéticos (con y sin microangiopatía).
- Las mediciones incluyeron los niveles de beta-tromboglobulina y las proporciones de agregado de plaquetas.
- Los cambios fueron monitoreados en pacientes diabéticos recientemente tratados con un mejor control de la glucosa en sangre.
Principales resultados:
- Los pacientes diabéticos con microangiopatía mostraron niveles significativamente elevados de beta-tromboglobulina.
- También se observaron agregados plaquetarios reversibles en estos pacientes.
- La mejora del control de la glucosa en sangre en nueve pacientes diabéticos recientemente tratados condujo a una disminución significativa en la beta-tromboglobulina plasmática.
Conclusiones:
- La microangiopatía diabética está asociada con evidencia de activación plaquetaria.
- La beta-tromboglobulina, una proteína específica de las plaquetas, puede servir como un marcador para esta activación.
- El grado de control bioquímico parece influir en la activación plaquetaria en pacientes diabéticos.
Videos de Conceptos Relacionados
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:28Diabetic Nephropathy
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...